Corvus Pharmaceuticals, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-06-30 was $23.05M.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $23.05M, a 27.94% decline from fiscal 2024.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2024 was $31.99M.
- Corvus Pharmaceuticals, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2016 was $125.78M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $23.05M 10-K · filed 2026-03-12 | |
| 2025-06-30 | $23.05M 10-Q · filed 2025-11-04 | |
| 2024-12-31 | $31.99M 10-K · filed 2026-03-12 | |
| 2016-12-31 | $125.78M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |